HENLIUS: VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL STUDY OF A BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION) SUCCESSFULLY COMPLETED

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.